Van Eck Associates 13F: Adds $3.1M to Biogen (BIIB) Stake
Van Eck Associates raised its Biogen Inc. holdings by 14,245 shares, totaling $233.3 million.
Reviewed by automated data checks against the source filing. How we make and check alerts
Van Eck Associates added 14,245 shares to its stake in Biogen Inc. ($BIIB), a 1.34% increase, according to a 13F filing with the SEC dated May 15, 2026. It reported 1,079,861 shares worth $233.93 million at the end of the quarter.
Since the filing, $BIIB is up 0.4% after 1 week, up 3.0% after 1 month and up 20.6% to date (from the $192.95 close on May 15, 2026).
Find the original: Van Eck Associates 13F filings on SEC EDGAR
BIIB
Biogen Inc.
Key Points
- Van Eck Associates increased its Biogen Inc. stake by 14,245 shares, bringing its total to 1,079,861 shares, valued at $233.3 million.
- Biogen Inc. has a market cap of $31.89 billion and a P/E ratio of 23.25, with a 52-week range between $121.05 and $218.06.
- Insiders at Biogen made several recent purchases, and analysts have set new price targets, with some maintaining 'buy' ratings.
Get $BIIB trade alerts by text
We text you when insiders, Congress or big funds trade $BIIB. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Biogen Inc. alert may contain errors. Disclosures
Van Eck Associates has boosted its position in Biogen Inc. (NasdaqGS:BIIB) by adding 14,245 shares. This increase brings the fund's total holdings to 1,079,861 shares, valued at approximately $233.3 million, according to the latest Form 13F filing with the SEC. This data reflects the fund's holdings as of the end of the reporting period and may not represent its current position.
Van Eck Associates vs. the S&P 500
Hypothetical returns from Van Eck Associates's disclosed trades, not real profit or advice. How we model this.
What Changed in Van Eck Associates' Biogen Position
Van Eck Associates increased its stake in Biogen by 1.3%, adding 14,245 shares to its portfolio. The fund now holds 1,079,861 shares, up from 1,065,616 shares previously. The total value of these holdings is about $233.3 million.
Other Institutional Activity in Biogen
BlackRock, Inc. grew its holdings in Biogen by 1,163,231 shares, ending with 15,974,601 shares worth about $2.93 billion. FMR LLC added 3,381,678 shares, raising its total to 12,807,541 shares valued at $2.35 billion, marking a 35.9% increase. Vanguard Capital Management LLC opened a new position with 9,537,417 shares, valued at approximately $1.75 billion. State Street Corp made a slight increase of 8,902 shares, bringing its total to 7,167,922 shares, worth about $1.31 billion.
Biogen Inc. Stock Down 8.0%
Shares of Biogen Inc. (NasdaqGS:BIIB) traded near $216.03 on Sunday. The company has a market capitalization of $31.89 billion, with a P/E ratio of 23.25 and a forward P/E of 12.99. Biogen's beta is a low 0.177, indicating less volatility compared to the market. The stock's 52-week range is between $121.05 and $218.06, with a 50-day moving average of $193.05 and a 200-day moving average of $176.24. The company maintains a healthy current ratio of 3.07 and a quick ratio of 2.03, with a debt-to-equity ratio of 35.18.
Recent Earnings
Biogen reported revenue of $9.94 billion, showing a modest growth of 1.9%. The company achieved a net margin of 13.8% and a return on equity of 7.7%. Its earnings per share stood at $9.29. The next earnings report is expected on July 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 26.3%. Revenue beat estimates by 7.7%.
-
Profit surprise
EBITDA missed by 7 percent. Operating income missed by 14 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
5 target raises, 1 target cut.
-
Earnings quality
Gross margin down 2.9 points. Operating margin down 14.1 points. Positive free cash flow.
Earnings Call Summary
Biogen had a very strong first quarter with growth products generating 851 million dollars, up 12 percent year-over-year. LEQEMBI sales surged 74 percent to 168 million dollars, benefiting from expansion in the U.S., Japan, and China. The company highlighted real-world evidence showing nearly 80 percent of LEQEMBI patients remain on therapy at 18 months, supporting the durability of treatment. High-dose SPINRAZA launched successfully with 20 percent of U.S. patients already switching, and the company is preparing for multiple pipeline readouts starting this year, including data on tau-targeting drug BIIB080 and lupus candidate Litifilimab.
Guidance Biogen reaffirmed its full-year guidance, confident in underlying business strength. The company expects to close the Apellis acquisition in the second quarter and will provide combined guidance after close. Management noted about 600 million dollars of contract manufacturing revenue expected this year, roughly two-thirds in the first half. They anticipate the acquisition will be accretive to earnings per share in 2027.
Slightly positive report. The quarter was acceptable, but the forward setup is not strong.
Insider Buying and Selling at Biogen Inc.
On June 9, 2026, several insiders at Biogen Inc. made notable transactions. Menelas Pangalos bought 2,370 shares, while Eric Rowinsky and Stephen Sherwin each purchased 1,505 shares. Maria Freire acquired 2,005 shares on the same day. These transactions were not made under Rule 10b5-1 plans.
Analysts Set New Price Targets
On June 18, 2026, Morgan Stanley maintained a 'hold' rating with a $224 price target for Biogen. Mizuho reaffirmed its 'buy' rating on June 15, setting a target of $221. Needham upgraded its rating to 'buy' with a $255 target on June 8. RBC Capital maintained its 'buy' rating with a $227 target on May 27. Overall, the consensus recommendation is a 'buy' with an average target price of $220.25, based on 31 analyst opinions.
About Biogen Inc.
Biogen Inc. is a healthcare company based in Cambridge, Massachusetts. It focuses on discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company offers treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, among others. Biogen collaborates with various companies to enhance its research and development efforts. It was founded in 1978 and employs about 7,500 people under the leadership of CEO Christopher A. Viehbacher.
Bottom Line
Van Eck Associates' decision to increase its stake in Biogen Inc. suggests confidence in the company's future. Investors closely watch these filings to gauge institutional sentiment. It's important to remember that 13F filings are backward-looking and may not reflect current positions. Biogen's stable financials and ongoing insider activities continue to make it a company of interest in the healthcare sector.
Related Filing Alerts
Source: Van Eck Associates's 13F filing on $BIIB (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Van Eck Associates 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts